CN102416003A - Method for preparing entecavir tablets - Google Patents
Method for preparing entecavir tablets Download PDFInfo
- Publication number
- CN102416003A CN102416003A CN2011104043182A CN201110404318A CN102416003A CN 102416003 A CN102416003 A CN 102416003A CN 2011104043182 A CN2011104043182 A CN 2011104043182A CN 201110404318 A CN201110404318 A CN 201110404318A CN 102416003 A CN102416003 A CN 102416003A
- Authority
- CN
- China
- Prior art keywords
- entecavir
- preparing
- tablet
- agent
- tabletting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000980 entecavir Drugs 0.000 title claims abstract description 50
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008215 water for injection Substances 0.000 claims abstract description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 17
- 239000000945 filler Substances 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 7
- 239000000853 adhesive Substances 0.000 claims abstract description 3
- 230000001070 adhesive effect Effects 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 18
- 229920003081 Povidone K 30 Polymers 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- 239000007916 tablet composition Substances 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 239000007921 spray Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000009835 boiling Methods 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 238000001694 spray drying Methods 0.000 abstract description 2
- 238000005550 wet granulation Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 description 12
- 238000005303 weighing Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a method for preparing entecavir tablets, which comprises the steps of taking a filling agent, a disintegrating agent and an adhesive in a prescription amount, and uniformly mixing to obtain auxiliary materials for later use; dispersing entecavir with a prescription dose into water for injection to obtain a main medicine for standby; uniformly spraying the main drug into the auxiliary material, adding the lubricant, uniformly mixing, measuring the content of the intermediate, and tabletting to obtain the tablet. The preparation method of the entecavir tablet adopts the spray gun to spray the main medicine into the medicinal auxiliary materials which are mixed in advance, thereby well solving the problem of uniformity of the tablet under the condition of low medicine content. In addition, the low-moisture microcrystalline cellulose PH-200LM is adopted as the entecavir tablet filling agent, the direct tabletting process does not need a drying process to carry out direct tabletting, and compared with the processes of wet granulation, fluidized bed, boiling granulation, spray drying and the like, the direct tabletting process is simpler and easier to implement, is suitable for industrial production, is beneficial to the control of product quality, saves energy, reduces consumption, reduces production cost and has good practicability.
Description
Technical field
The invention belongs to the pharmaceutical preparations technology field, be specifically related to a kind of method for preparing the Entecavir tablet.
Background technology
Entecavir is a kind of IUDR analog that can effectively suppress hepatitis B replication, has very strong anti-HBV effect.3 stages such as initial, the reversal of viral of the dna replication dna of HBV and DNA normal chain is synthetic are all played inhibitory action; The effect of Entecavir is the archaeal dna polymerase and counter-rotating virus through suppressing HBV; Thereby the DNA minus strand that the gene RNA reversal of viral duplicates HBV before suppressing; And then suppress the synthetic of normal chain, thereby the extension and the assembling of the DNA chain of blocking-up HBV.Clinical verified to the hepatitis B virus good inhibition effect.At present clinically be used for the treatment adult and continue to increase with serum transaminase, or liver histological is that the chronic viral hepatitis B of activeness pathological changes infects with virus replication is active.
It is very high that Entecavir suppresses the active effect of hepatitis B virus, and low-down metering just can reach desired effects.In the Entecavir formulation; Content in its single dose is very little; Specifications such as clinical 0.5mg commonly used, 1mg; So low metering makes its various preparations usually, and especially the content of effective medicinal ingredient Entecavir is difficult to keep constant in the tablet between each single agent, so require its uniformity of dosage units of inspection to low dose of oral solid formulation in the Chinese Pharmacopoeia.
Summary of the invention
Goal of the invention: to the deficiency that exists in the prior art; The purpose of this invention is to provide a kind of method for preparing the Entecavir tablet; With the uniformity problem of solution tablet under the low situation of medicament contg, and realize need not to carry out the stoving process operation, can carry out direct compression.
Technical scheme: in order to realize the foregoing invention purpose, technical scheme provided by the invention is:
A kind of method for preparing the Entecavir tablet: get filler, disintegrating agent and the binding agent of recipe quantity, mix homogeneously, it is subsequent use to get adjuvant; The Entecavir of recipe quantity is distributed in the water for injection, and it is subsequent use to get principal agent; Principal agent evenly is sprayed in the adjuvant, adds lubricant, mix homogeneously is measured intermediate content, tabletting, both;
The Entecavir tablet is formed 0.1%～0.8% Entecavir by following components by mass percentage, 80%～95% filler, 2%～5% disintegrating agent, 2～6% binding agents, 0.1%～1% lubricant; Described filler is microcrystalline Cellulose PH-200LM; Described disintegrating agent is one or more in cross-linking sodium carboxymethyl cellulose (Ac-Di-Sol), polyvinylpolypyrrolidone, the crosslinked carboxymethyl fecula sodium; Described binding agent is one or more in 30 POVIDONE K 30 BP/USP 30, starch, the dextrin; Described lubricant is one or more in magnesium stearate, polyethylene glycol 6000, the poloxamer 188.
Entecavir tablet formulation specification is 0.1 ~ 1mg.Tabletting hardness is 5 ~ 8kg.
Used disintegrating agent is preferably cross-linking sodium carboxymethyl cellulose, and adhesive therefor is preferably 30 POVIDONE K 30 BP/USP 30, the magnesium stearate that with lubricator is preferably.
The present invention is scattered in Entecavir in the water for injection in Entecavir tablet preparation process, adopts spray gun to spray into adjuvant, has well solved the uniformity problem of tablet under the low situation of medicament contg; In addition, adopt low moisture microcrystalline Cellulose PH-200LM, compare other technology, need not drying course as filler, can direct compression, simplified processing step, reduced production cost when raising the efficiency, have good practicability.
Beneficial effect: Entecavir method for preparing tablet thereof of the present invention adopts spray gun principal agent to be sprayed in the pharmaceutic adjuvant that is pre-mixed, and has well solved the uniformity problem of tablet under the low situation of medicament contg.In addition; Adopt low moisture microcrystalline Cellulose PH-200LM to need not the stoving process direct compression as the Entecavir tablet filler; This direct compression technology is more simple than technologies such as wet granulation, sulfuration bed, boiling granulating, spray dryinges; Be fit to suitability for industrialized production, help controllable quality, reduce production costs with energy-saving and cost-reducing.
The specific embodiment
Explain the present invention below in conjunction with specific embodiment.
Embodiment 1
Each component of Entecavir tablet consists of: 10g Entecavir, 8.5kg microcrystalline Cellulose PH-200LM, 300gAc-Di-Sol, 500g 30 POVIDONE K 30 BP/USP 30,50g magnesium stearate.
Take by weighing under 8.5kg microcrystalline Cellulose PH-200LM, 3gAc-Di-Sol, 6g 30 POVIDONE K 30 BP/USP 30 room temperatures with three-dimensional hybrid device mix homogeneously, incorporation time is 10min, and is subsequent use; Disperse the 10g Entecavir with 500ml water for injection, jitter time is 10min, and is subsequent use; The water for injection that above-mentioned 500ml is contained principal agent is sprayed in the above-mentioned adjuvant, adds the magnesium stearate of 50g again, and with three-dimensional hybrid device mix homogeneously, incorporation time is 5min.Mixing.The mould tabletting, is measured intermediate content by totally 5 ten thousand; Wherein, tabletting hardness is 6kg, and mould is 7mm.
Embodiment 2:
The constituent of Entecavir tablet is: 70g Entecavir, 9kg microcrystalline Cellulose PH-200LM, 200gAc-Di-Sol, 200g 30 POVIDONE K 30 BP/USP 30,100g magnesium stearate, water for injection 800ml.
Take by weighing under 9kg microcrystalline Cellulose PH-200LM, 500gAc-Di-Sol, 600g 30 POVIDONE K 30 BP/USP 30 room temperatures with three-dimensional hybrid device mix homogeneously, incorporation time is 5min, and is subsequent use; Disperse the 100g Entecavir with 800ml water for injection, jitter time is 5min, and is subsequent use; The water for injection that above-mentioned 800ml is contained principal agent is sprayed in the above-mentioned adjuvant, adds the magnesium stearate of 50g again, and with three-dimensional hybrid device mix homogeneously, incorporation time is 2min.Mixing.The mould tabletting, is measured intermediate content by totally 5 ten thousand; Wherein, tabletting hardness is 7kg, and mould is 8mm.
Embodiment 3:
Each component of Entecavir tablet consists of: 0.7g Entecavir, 80g microcrystalline Cellulose PH-200LM, 3gAc-Di-Sol, 5g 30 POVIDONE K 30 BP/USP 30,0.9g magnesium stearate, 700ml water for injection.
Take by weighing under 8kg microcrystalline Cellulose PH-200LM, 500gAc-Di-Sol, 600g 30 POVIDONE K 30 BP/USP 30 room temperatures with three-dimensional hybrid device mix homogeneously, incorporation time is 30min, and is subsequent use; Disperse the 80g Entecavir with 700ml water for injection, jitter time is 30min, and is subsequent use; The water for injection that above-mentioned 700ml is contained principal agent is sprayed in the above-mentioned adjuvant, adds the magnesium stearate of 100g again, and with three-dimensional hybrid device mix homogeneously, incorporation time is 10min, mixing.The mould tabletting, is measured intermediate content by totally 5 ten thousand; Wherein, tabletting hardness is 8kg, and mould is 9mm.
Embodiment 4:
Each component of Entecavir tablet consists of: 80g Entecavir, 9.22kg microcrystalline Cellulose PH-200LM, 300gAc-Di-Sol, 300g 30 POVIDONE K 30 BP/USP 30,100g magnesium stearate, 500ml water for injection.
Take by weighing under 9kg microcrystalline Cellulose PH-200LM, 300gAc-Di-Sol, 300g 30 POVIDONE K 30 BP/USP 30 room temperatures with three-dimensional hybrid device mix homogeneously, incorporation time is 25min, and is subsequent use; Disperse the 80g Entecavir with 500ml water for injection, jitter time is 20min, and is subsequent use; The water for injection that above-mentioned 500ml is contained principal agent is sprayed in the above-mentioned adjuvant, adds the magnesium stearate of 100g again, and with three-dimensional hybrid device mix homogeneously, incorporation time is 15min, mixing.The mould tabletting, is measured intermediate content by totally 5 ten thousand; Wherein, tabletting hardness is 7.5kg, and mould is 8mm.
Embodiment 5:
Each component of Entecavir tablet consists of: 10g Entecavir, 9.2kg microcrystalline Cellulose PH-200LM, 300g polyvinylpolypyrrolidone, 300g dextrin, 50g polyethylene glycol 6000,300ml water for injection.
Take by weighing under 9.2kg microcrystalline Cellulose PH-200LM, 300g polyvinylpolypyrrolidone, the 300g dextrin room temperature with three-dimensional hybrid device mix homogeneously, incorporation time is 20min, and is subsequent use; Disperse the 10g Entecavir with 300ml water for injection, jitter time is 15min, and is subsequent use; The water for injection that above-mentioned 300ml is contained principal agent is sprayed in the above-mentioned adjuvant, adds the polyethylene glycol 6000 of 50g again, and with three-dimensional hybrid device mix homogeneously, incorporation time is 5min, mixing.The mould tabletting, is measured intermediate content by totally 5 ten thousand; Wherein, tabletting hardness is 6.5kg, and mould is 7mm.
Embodiment 6:
Each component of Entecavir tablet consists of: 50g Entecavir, 9.5kg microcrystalline Cellulose PH-200LM, 300g crosslinked carboxymethyl fecula sodium, 300g starch, 50g poloxamer 188,400ml water for injection.
Take by weighing under 9.5kg microcrystalline Cellulose PH-200LM, 300g crosslinked carboxymethyl fecula sodium, the 300g starch room temperature with three-dimensional hybrid device mix homogeneously, incorporation time is 25min, and is subsequent use; Disperse the 50g Entecavir with 400ml water for injection, jitter time is 20min, and is subsequent use; The water for injection that above-mentioned 400ml is contained principal agent is sprayed in the above-mentioned adjuvant, adds the poloxamer 188 of 50g again, and with three-dimensional hybrid device mix homogeneously, incorporation time is 10min.Mixing.The mould tabletting, is measured intermediate content by totally 5 ten thousand; Wherein, tabletting hardness is 7kg, and mould is 8mm.
Claims (6)
1. method for preparing the Entecavir tablet is characterized in that: get filler, disintegrating agent and the binding agent of recipe quantity, mix homogeneously, adjuvant is subsequent use; The Entecavir of recipe quantity is distributed in the water for injection, and it is subsequent use to get principal agent; Principal agent evenly is sprayed in the adjuvant, adds lubricant, mix homogeneously is measured intermediate content, tabletting, both; Wherein, the Entecavir tablet, raw material is made up of following components by mass percentage: 0.1%～0.8% Entecavir, 80%～95% filler, 2%～5% disintegrating agent, 2～6% binding agents, 0.1%～1% lubricant; Described filler is microcrystalline Cellulose PH-200LM; Described disintegrating agent is one or more in cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone, the crosslinked carboxymethyl fecula sodium; Described binding agent is one or more in 30 POVIDONE K 30 BP/USP 30, starch, the dextrin; Described lubricant is one or more in magnesium stearate, polyethylene glycol 6000, the poloxamer 188.
2. the method for preparing the Entecavir tablet according to claim 1 is characterized in that: Entecavir tablet formulation specification is 0.1 ~ 1mg.
3. the method for preparing the Entecavir tablet according to claim 1 is characterized in that: tabletting hardness is 5 ~ 8kg.
4. the method for preparing the Entecavir tablet according to claim 1 is characterized in that: used disintegrating agent is a cross-linking sodium carboxymethyl cellulose.
5. the method for preparing the Entecavir tablet according to claim 1 is characterized in that: adhesive therefor is a 30 POVIDONE K 30 BP/USP 30.
6. the method for preparing the Entecavir tablet according to claim 1 is characterized in that: institute with lubricator is magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104043182A CN102416003A (en) | 2011-12-08 | 2011-12-08 | Method for preparing entecavir tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104043182A CN102416003A (en) | 2011-12-08 | 2011-12-08 | Method for preparing entecavir tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102416003A true CN102416003A (en) | 2012-04-18 |
Family
ID=45940807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104043182A Pending CN102416003A (en) | 2011-12-08 | 2011-12-08 | Method for preparing entecavir tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102416003A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104258406A (en) * | 2014-09-15 | 2015-01-07 | 山东大学 | Entecavir pharmaceutical composition and preparation method thereof |
| CN104784136A (en) * | 2015-04-20 | 2015-07-22 | 山东新时代药业有限公司 | Entecavir tablets |
| CN106580899A (en) * | 2016-11-02 | 2017-04-26 | 沈阳药科大学 | Method for preparing imidafenacin tablet |
| CN110420188A (en) * | 2019-08-06 | 2019-11-08 | 浙江爱诺生物药业股份有限公司 | A method of improving Entecavir tablet uniformity of dosage units |
| CN112535736A (en) * | 2020-12-14 | 2021-03-23 | 石家庄四药有限公司 | Entecavir composition and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064810A (en) * | 1991-03-12 | 1992-09-30 | 阿克佐公司 | The dry pharmaceutical preparations of low dosage |
| CN1371276A (en) * | 1999-07-26 | 2002-09-25 | 埃迪克埃迪法姆药品实验室 | Low-dose tablets and preparation method |
| CN1813753A (en) * | 2000-02-29 | 2006-08-09 | 布里斯托尔-迈尔斯斯奎布公司 | Low dose entecavir formulation and use |
| CN1867323A (en) * | 2003-11-10 | 2006-11-22 | 埃法尔姆公司 | Low-dose tablets having a network of polymers |
| CN101181224A (en) * | 2007-12-07 | 2008-05-21 | 杨喜鸿 | Solid dispersion of entecavir, pharmaceutical composition and preparation method as well as uses thereof |
| CN101244044A (en) * | 2008-03-24 | 2008-08-20 | 杭州盛友医药技术开发有限公司 | Entecavir dispersible tablet and preparation thereof |
| CN101371841A (en) * | 2007-08-23 | 2009-02-25 | 浙江医药股份有限公司新昌制药厂 | Crystallization type Entecavir formulation as well as preparation method and use thereof |
| CN102106856A (en) * | 2010-06-29 | 2011-06-29 | 江苏正大天晴药业股份有限公司 | Entecavir medicinal composition and preparation method thereof |
-
2011
- 2011-12-08 CN CN2011104043182A patent/CN102416003A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064810A (en) * | 1991-03-12 | 1992-09-30 | 阿克佐公司 | The dry pharmaceutical preparations of low dosage |
| CN1371276A (en) * | 1999-07-26 | 2002-09-25 | 埃迪克埃迪法姆药品实验室 | Low-dose tablets and preparation method |
| CN1813753A (en) * | 2000-02-29 | 2006-08-09 | 布里斯托尔-迈尔斯斯奎布公司 | Low dose entecavir formulation and use |
| CN1867323A (en) * | 2003-11-10 | 2006-11-22 | 埃法尔姆公司 | Low-dose tablets having a network of polymers |
| CN101371841A (en) * | 2007-08-23 | 2009-02-25 | 浙江医药股份有限公司新昌制药厂 | Crystallization type Entecavir formulation as well as preparation method and use thereof |
| CN101181224A (en) * | 2007-12-07 | 2008-05-21 | 杨喜鸿 | Solid dispersion of entecavir, pharmaceutical composition and preparation method as well as uses thereof |
| CN101244044A (en) * | 2008-03-24 | 2008-08-20 | 杭州盛友医药技术开发有限公司 | Entecavir dispersible tablet and preparation thereof |
| CN102106856A (en) * | 2010-06-29 | 2011-06-29 | 江苏正大天晴药业股份有限公司 | Entecavir medicinal composition and preparation method thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104258406A (en) * | 2014-09-15 | 2015-01-07 | 山东大学 | Entecavir pharmaceutical composition and preparation method thereof |
| CN104784136A (en) * | 2015-04-20 | 2015-07-22 | 山东新时代药业有限公司 | Entecavir tablets |
| CN106580899A (en) * | 2016-11-02 | 2017-04-26 | 沈阳药科大学 | Method for preparing imidafenacin tablet |
| CN106580899B (en) * | 2016-11-02 | 2020-05-01 | 沈阳药科大学 | Method for preparing imidafenacin tablets |
| CN110420188A (en) * | 2019-08-06 | 2019-11-08 | 浙江爱诺生物药业股份有限公司 | A method of improving Entecavir tablet uniformity of dosage units |
| CN112535736A (en) * | 2020-12-14 | 2021-03-23 | 石家庄四药有限公司 | Entecavir composition and preparation method thereof |
| CN112535736B (en) * | 2020-12-14 | 2023-08-29 | 石家庄四药有限公司 | Entecavir composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101057849A (en) | Slow-releasing preparation containing metformin hydrochloride and glipizide and its preparation method | |
| CN102416003A (en) | Method for preparing entecavir tablets | |
| HRP20161262T1 (en) | Ulipristal acetate tablets | |
| CN103520169B (en) | Mirtazapine tablet and preparation method thereof | |
| MX2012014402A (en) | Composition for preventing or treating osteoporosis, and manufacturing method therefor. | |
| CN1850069A (en) | Method for preparing Tengchasu dispersibletablet and its use | |
| CN102349915A (en) | Acetaminophen, caffeine, chlorphenamine maleate, and vitamin C preparation and preparation method thereof | |
| CN103417501B (en) | Topiramate pharmaceutical composition | |
| CN101411702B (en) | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof | |
| CN100386086C (en) | Dispersed compound tablet of glycyrrhizic acid and glycyrrhizinate and its preparing process | |
| CN105663131B (en) | A kind of Repaglinide metformin tablet medicament composition and preparation method thereof | |
| CN106902097B (en) | A pharmaceutical composition for improving bioavailability of medicine | |
| CN105412132A (en) | Compound invermectin slow-release granules and preparation method thereof | |
| CN109513008B (en) | A kind of pharmaceutical composition for treating idiopathic interstitial pneumonia and preparation method thereof | |
| CN1481805A (en) | Medication for hepatitis and its preparation method | |
| CN103142583A (en) | Levetiracetam-containing pharmaceutical composition and preparation method thereof | |
| CN101653423A (en) | Lacidipine tablets and preparation method thereof | |
| CN102218064B (en) | Pharmaceutical combination with repaglinide and metformin as active components and preparation method thereof | |
| CN101069691A (en) | Capsule preparation for treating gastric ulcer and preparing method | |
| CN103622930B (en) | Metformin hydrochloride slow release preparation and preparation method thereof | |
| CN105687218A (en) | Glipizide/acarbose hypoglycemic oral preparation composition and preparation method thereof | |
| CN204072820U (en) | A kind of compound recipe three-layer tablet being used for the treatment of helicobacter pylori | |
| KR101441355B1 (en) | Bilayered tablet comprising repaglinide and metformin and the preparation method thereof | |
| CN101467988B (en) | Medicament composition containing paracetamol and pseudoephedrine hydrochloride and preparation method thereof | |
| CN106822250A (en) | A kind of Brown Mixtura and its preparation technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120418 |